Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

ABSTRACT:

Background

Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis.

Objectives

To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA.

Methods

Phase 3 trial participants entered a randomized placebo-controlled period then an open-label extension (OLE) with GA.

Results

Overall, 208 out of 251 (82.9%) randomized participants entered the OLE; 24 out of 101 (23.8%, ES) and 28 out of 107 (26.2%, DS) participants completed the OLE. Median GA treatment was 9.8 (0.1-26.3) years. Annualized change in Expanded Disability Status Scale (EDSS) score was lower with ES versus DS (p = 0.0858: full study; p = 0.002; Year 5). Participants with improved/stable EDSS was

SUBMITTER: Ford CC 

PROVIDER: S-EPMC9442630 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature